BLTE
BELITE BIO, INC
Overview
BELITE BIO, INC is a Healthcare company operating in Biotechnology with a $5.90B market cap.
Most recent earnings call: Q1 FY26 on May 20, 2026.
15 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-2011 Q&A exchanges
- Q4 FY2025Earnings2026-03-0318 Q&A exchanges
- Q3 FY2025Earnings2025-11-109 Q&A exchanges
- Q2 FY2025Earnings2025-08-1114 Q&A exchanges
- Q1 FY2025Earnings2025-05-1520 Q&A exchanges
- Q4 FY2024Earnings2025-03-1718 Q&A exchanges
- Q3 FY2024Earnings2024-11-1220 Q&A exchanges
- Q2 FY2024Earnings2024-08-1216 Q&A exchanges
- Q1 FY2024Earnings2024-05-149 Q&A exchanges
- Q4 FY2023Earnings2024-03-1211 Q&A exchanges
- Q3 FY2023Earnings2023-11-1416 Q&A exchanges
- Q2 FY2023Earnings2023-08-1316 Q&A exchanges
- Q1 FY2023Earnings2023-05-1421 Q&A exchanges
- Q4 FY2022Earnings2023-04-0317 Q&A exchanges
- Q2 FY2022Earnings2022-08-139 Q&A exchanges
History
Earnings history
Reported quarters with consensus, surprise, and 1-day reaction context.
Track Record
SampleSpoken Alpha tracks BLTE's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.23 | $1.91 | +16.9% | +2.3% | +4.8% |
| Q4 FY2026 | $2.12 | $1.89 | +12.4% | -0.7% | -0.4% |
| Q3 FY2026 | $2.23 | $1.89 | +18.0% | -3.7% | -2.0% |
| Q2 FY2026 | $2.09 | $1.77 | +18.3% | +4.6% | +4.9% |
| Q1 FY2025 | $2.06 | $1.79 | +15.2% | -2.6% | -0.3% |
| Q4 FY2025 | $2.20 | $2.03 | +8.4% | +1.6% | +4.0% |
| Q3 FY2025 | $2.02 | $1.82 | +10.9% | +1.1% | +3.6% |
| Q2 FY2025 | $2.30 | $2.04 | +12.8% | -0.3% | -1.7% |
| Q1 FY2024 | $2.46 | $2.09 | +17.7% | -0.1% | -1.8% |
| Q4 FY2024 | $2.09 | $1.93 | +8.3% | +2.6% | -0.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BLTE.
$ curl https://api.spokenalpha.com/v1/companies/BLTEFAQ
Frequently asked about BLTE
Where can I find BELITE BIO, INC's (BLTE) earnings call transcripts?
Spoken Alpha indexes BLTE's earnings call transcripts at https://spokenalpha.com/companies/BLTE. Each call links to attributed speakers and parsed analyst Q&A. BELITE BIO, INC's own investor relations page is at https://investors.belitebio.com/.
When was BELITE BIO, INC's most recent earnings call?
BELITE BIO, INC (BLTE) held its most recent earnings call on 2026-05-20, covering fiscal Q1 2026.
What sector is BLTE in?
BELITE BIO, INC (BLTE) operates in the Healthcare sector (Biotechnology industry).